We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why
Read MoreHide Full Article
Shares of Corcept Therapeutics Incorporated (CORT - Free Report) have rallied 50.5% in the past three months compared with the industry’s increase of 11.4%.
Corcept’s only marketed drug, Korlym, is approved for the once-daily oral treatment of hyperglycemia — secondary to hypercortisolism — in adult patients with endogenous Cushing’s syndrome who are suffering from type II diabetes or glucose intolerance and who have already failed surgery or are unsuitable for the same.
In the first nine months of 2020, Korlym generated sales worth $268.1 million, reflecting an increase of 22.6% year over year. Revenues from the sale of the drug are used to fund the company’s operations.
Notably, Corcept’s lead pipeline candidate, relacorilant, is being evaluated in the phase III GRACE study to treat Cushing’s syndrome. The company plans to submit a new drug application for relacorilant in the second quarter of 2022.
Corcept is also currently enrolling in the phase III study GRADIENT for evaluating relacorilant in patients whose Cushing’s syndrome is caused by adrenal adenoma, at sites across the United States, Europe and Israel.
Meanwhile, the company completed enrollment in a phase II study on relacorilant in combination with Celgene's (now part of Bristol Myers [(BMY - Free Report) ]) Abraxane for the treatment of metastatic ovarian cancer with results expected in first-half 2021. The combo of relacorilant plus Abraxane is also being evaluated for addressing patients with metastatic pancreatic cancer.
Also, during the third quarter of 2020, the company initiated a phase Ib study on relacorilant plus Merck’s (MRK - Free Report) PD-1 checkpoint inhibitor Keytruda to address patients with metastatic or unresectable adrenal cancer. Successful development of relacorilant for additional indications will be an added boost to the company and should drive the stock in the days ahead.
Apart from relacorilant, Corcept’s other pipeline candidates include exicorilant and miricorilant, which are also progressing well.
The company is conducting an open-label, dose-finding study on exicorilant in combination with Pfizer’s (PFE - Free Report) Xtandi for treating patients with metastatic castration-resistant prostate cancer.
Corcept is currently enrolling patients in a phase II GRATITUDE study on miricorilant for addressing the reversal of antipsychotic-induced weight gain (“APIWG”). In September 2020, the company enrolled the first patient in the phase II GRATITUDE 2 study of miricorilant to reverse the long-standing APIWG.
Notably, Korlym has been performing well since its launch and has seen a strong uptake. Corcept’s pipeline candidates are also progressing well, which are key for the company’s long-term growth. However, the company remains solely dependent on Korlym for revenues. A decline in Korlym sales will thus hurt the company’s growth prospects in the future ahead.
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why
Shares of Corcept Therapeutics Incorporated (CORT - Free Report) have rallied 50.5% in the past three months compared with the industry’s increase of 11.4%.
Corcept’s only marketed drug, Korlym, is approved for the once-daily oral treatment of hyperglycemia — secondary to hypercortisolism — in adult patients with endogenous Cushing’s syndrome who are suffering from type II diabetes or glucose intolerance and who have already failed surgery or are unsuitable for the same.
In the first nine months of 2020, Korlym generated sales worth $268.1 million, reflecting an increase of 22.6% year over year. Revenues from the sale of the drug are used to fund the company’s operations.
Notably, Corcept’s lead pipeline candidate, relacorilant, is being evaluated in the phase III GRACE study to treat Cushing’s syndrome. The company plans to submit a new drug application for relacorilant in the second quarter of 2022.
Corcept is also currently enrolling in the phase III study GRADIENT for evaluating relacorilant in patients whose Cushing’s syndrome is caused by adrenal adenoma, at sites across the United States, Europe and Israel.
Meanwhile, the company completed enrollment in a phase II study on relacorilant in combination with Celgene's (now part of Bristol Myers [(BMY - Free Report) ]) Abraxane for the treatment of metastatic ovarian cancer with results expected in first-half 2021. The combo of relacorilant plus Abraxane is also being evaluated for addressing patients with metastatic pancreatic cancer.
Also, during the third quarter of 2020, the company initiated a phase Ib study on relacorilant plus Merck’s (MRK - Free Report) PD-1 checkpoint inhibitor Keytruda to address patients with metastatic or unresectable adrenal cancer. Successful development of relacorilant for additional indications will be an added boost to the company and should drive the stock in the days ahead.
Apart from relacorilant, Corcept’s other pipeline candidates include exicorilant and miricorilant, which are also progressing well.
The company is conducting an open-label, dose-finding study on exicorilant in combination with Pfizer’s (PFE - Free Report) Xtandi for treating patients with metastatic castration-resistant prostate cancer.
Corcept is currently enrolling patients in a phase II GRATITUDE study on miricorilant for addressing the reversal of antipsychotic-induced weight gain (“APIWG”). In September 2020, the company enrolled the first patient in the phase II GRATITUDE 2 study of miricorilant to reverse the long-standing APIWG.
Notably, Korlym has been performing well since its launch and has seen a strong uptake. Corcept’s pipeline candidates are also progressing well, which are key for the company’s long-term growth. However, the company remains solely dependent on Korlym for revenues. A decline in Korlym sales will thus hurt the company’s growth prospects in the future ahead.
Corcept Therapeutics Incorporated Price
Corcept Therapeutics Incorporated price | Corcept Therapeutics Incorporated Quote
Zacks Rank
Corcept currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>